Business Context and Reporting Period
This Form 8-K Current Report was filed by Emerald Bioscience, Inc. (not Skye Bioscience, Inc.) on November 21, 2019. The report details the entry into a Material Definitive Agreement and the closing of a securities offering.
Key Financial Metrics
- Offering Size: $2.0 million gross offering price.
- Securities Issued: 8.0 million shares of Common Stock at $0.25 per share and 8.0 million Warrants.
- Warrant Terms: Exercise price of $0.35 per share; five-year exercise term.
- Net Proceeds: Estimated at approximately $1.95 million after transaction expenses (assuming no warrant exercise).
- Use of Proceeds: General corporate purposes, including working capital.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the company.
Material Changes
The primary material change is the capital raise executed on November 20, 2019, and closed on November 21, 2019. This transaction increases the company's outstanding share count by 8.0 million shares and introduces 8.0 million warrants into the capital structure.
Guidance, Outlook, and Risks
- Management Commentary: The Company intends to use net proceeds for working capital and general corporate purposes.
- Warrant Restrictions: Warrant holders are prohibited from exercising if it results in beneficial ownership exceeding 4.99% or 9.99% of outstanding Common Stock.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties that may cause actual results to differ from expectations.
- Regulatory Status: The securities were sold pursuant to an effective registration statement on Form S-1 declared effective by the SEC on October 28, 2019, and November 13, 2019.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-closing to assess dilution impact.
- Confirm the actual net proceeds received versus the estimated $1.95 million.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants.
- Check subsequent filings for any exercise of the 8.0 million warrants issued.
- Confirm the company's current cash position and runway given the stated use of proceeds for working capital.